Company Analysis

Design Therapeutics, Inc. (DSGN)

Nasdaq: DSGN · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 2020
Grade5.6
◀ Past 6.9● Present 6.5▶ Future 4.1
6 est.

Who runs Design Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Shah Pratik
President, CEO and Chairperson. First filing Mar 2021, latest Jan 5, 2026, 1 filing in all.
Officers reporting now
4
of 11 people with a filing in the last fifteen months
Directors reporting now
7
18 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Shah PratikPresident, CEO and ChairpersonMar 2021Jan 5, 2026none
Jeffries SeanChief Operating OfficerMar 2021Jan 5, 2026none
Burgess JulieChief Accounting OfficerSep 2021Jan 5, 2026none
Storgard ChrisChief Medical OfficerMay 2025Jan 5, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Berger Heather A.directorJun 2021Jun 11, 2026none
George SimeondirectorMar 2021Jun 11, 2026none
Gover Justin D.directorSep 2025Jun 11, 2026none
Lappe Rodney WdirectorMar 2021Jun 11, 2026none
Schmid John P.directorMar 2021Jun 11, 2026none
Shapiro DaviddirectorApr 2026Jun 11, 2026none
William ArsanidirectorMar 2021Aug 14, 2025none
Earlier names on the record19, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton DSGN · research, not advice